S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Health and Healthcare

Myriad’s Alarming Alzheimer’s Forecasts

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Updated Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Myriad Genetics, Inc. (MYGN-NASDAQ) has issued a press release discussing a new study showing that the potential savings to the US healthcare system alone could be $4.0 Trillion from 2010 to 2050.  It estimates that in 2030 the rate from today’s 5.1 million Americans with Alzheimer’s will grow to 7.7 million and then to 16 million by 2050.

What Myriad is doing is essentially promoting its Flurizan (currently in Phase II’s) and it is trying to speed things up by noting that the delay of even a year could have tremendous expense ramifications.  We noted many of the other company names working in the sector after Barron’s ran a cover story on this epidemic that Barron’s left off.

These current numbers and projections are seeming to get worse and worse each year

Jon C. Ogg
May 15, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

Barron’s Alzheimer’s Article Only Scratches the Surface

Stock Tickers: WYE, NRMX, ELN, NVS, PFE, LLY, JNJ, AZN, TRGT, SNH, SRZ, BKD, ALC, HCR, ESC, MYGN, FRX, NYMX,…
Lee Jackson |

Cowen Thinks 3 Life Science Stocks Can Beat Earnings Estimates

In a new research report, Cowen analysts focus on three life science stocks that they think could beat current consensus…
Douglas A. McIntyre |

Barron’s Berkshire Hathaway Bashing Could Be Your Gain (BRK/A, BRK/B, BRK-A, BRK-B)

Berkshire Hathaway (NYSE:BRK/A) (NYSE:BRK/B) shares fell today after Barron’s called for investors to sell Warren Buffett’s growth machine.  This seemed…
Douglas A. McIntyre |

Alzheimer’s Data Pumps Medivation & Neurochem (MDVN, NRMX)

Some new data is helping two small biotech stocks today at the Alzheimer’s Association International Conference on Prevention of Dementia…
Douglas A. McIntyre |

Barron’s Keynotes (April 14, 2007)

This weekend’s edition of Barron’s hit on some key names. The cover story is on Adobe (ADBE-NASDAQ) with the prediction…
Jon C. Ogg |

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

ThinkstockSarepta Therapeutics Inc. (NASDAQ: SRPT) should have received a huge boost from “The Barron’s Effect” on Monday. The financial publication,…
Douglas A. McIntyre |

Alternative Energy Watch: BrightSource Files for IPO; IEA Publishes Roadmap for Biofuels; Chinese Battery Maker De-listed (CRTP, GOOG, PCG, EIX, GS, C, DB)

Today’s alternative energy watch begins with a look at the IPO filing by solar thermal maker BrightSource and then examines…
Douglas A. McIntyre |

Barron’s Blackstone IPO Cover Story: Crystal Ball or Tabloid? (BX, GOOG, GS, AAPL)

It’s no shock that Barron’s decided to make its cover story that of the Stephen Schwarzman picture from the Blackstone…
William Blair Initiates Cameco at Outperform With $165 Fair Value: Is Uranium Entering a Supercycle?
David Moadel |

William Blair Initiates Cameco at Outperform With $165 Fair Value: Is Uranium Entering a Supercycle?

Cameco (NYSE:CCJ | CCJ Price Prediction) stock just earned a strong endorsement from William Blair, which initiated coverage with an…

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618